

Hematology

			Clinical Proof of Concept	Pivotal	Approved
MPNs	Jakafi® (ruxolitinib)¹ JAK1/JAK2	Myelofibrosis ² , polycythemia vera ²			
	Jakafi XR™ (ruxolitinib XR)¹ JAK1/JAK2	Myelofibrosis ² , polycythemia vera ²			
	INCA033989 mutCALR	CALR-mutated myelofibrosis or ET ± ruxolitinib			
	INCA035784³ mutCALRxCD3	CALR-mutated myelofibrosis or ET			
	INCB160058 JAK2 V617F	JAK2 V617F-mutated MPNs ± ruxolitinib			
GVHD	Jakafi® (ruxolitinib)¹ JAK1/JAK2	GVHD ²			
	Jakafi XR™ (ruxolitinib XR)¹ JAK1/JAK2	GVHD ²			
	Niktimvo™ (axatilimab-csfr)⁴ CSF-1R	3L+ chronic GVHD ²			
	axatilimab⁴ CSF-1R	1L chronic GVHD			
		1L chronic GVHD + ruxolitinib			
Lymphomas/Leukemias	Monjuvi® (tafasitamab-cxix) CD19	r/r DLBCL ^{2,5,6} , r/r follicular lymphoma ^{2,6,7}			
	Pemazyre® (pemigatinib) FGFR1/2/3	MLNs with <i>FGFR1</i> rearrangement ^{2,7}			
	Iclusig® (ponatinib)⁸ BCR-ABL	Chronic myeloid leukemia ⁶ , Ph+ ALL ⁶			
	tafasitamab CD19	1L DLBCL			
	INCA036873³ CD70xCD3	B-cell and T-cell lymphomas			
Other	tafasitamab CD19	Immune thrombocytopenia, wAIHA			

16
Molecular
Targets

19
Clinical
Compounds

10
Approved
Products

As of May 4, 2026

Please refer to local prescribing information for more information, including full safety information, on Incyte's marketed medicines, or on medicines marketed by Incyte's collaboration partners.

1. Jakafi® and Jakafi XR™ are marketed by Incyte in the U.S.; ruxolitinib is licensed to Novartis outside the U.S. and marketed as Jakavi® **2.** Approved in the U.S. **3.** Development in collaboration with Merus **4.** In collaboration with Syndax **5.** Approved in Canada **6.** Approved in Europe **7.** Approved in Japan **8.** European rights to ponatinib licensed from Takeda **9.** Licensed from MacroGenics **10.** Approved in multiple territories, including the U.S., Canada, Europe, and Japan **11.** Worldwide rights to baricitinib licensed to Lilly **12.** Approved in multiple territories globally **13.** Worldwide rights to capmatinib licensed to Novartis **14.** IPF study currently led and funded by Syndax

1L, first-line; 3L+, third-line or later; AD, atopic dermatitis; ALL, acute lymphoblastic leukemia; CALR, calreticulin; DLBCL, diffuse large B-cell lymphoma; ET, essential thrombocythemia; FGFR, fibroblast growth factor receptor; GVHD, graft-versus-host disease; IPF, idiopathic pulmonary fibrosis; MLNs, myeloid/lymphoid neoplasms; MPNs, myeloproliferative neoplasms; mut, mutant; PDAC, pancreatic ductal adenocarcinoma; Ph+, Philadelphia chromosome-positive; PROC, platinum-resistant ovarian cancer; r/r, relapsed or refractory; wAIHA, warm autoimmune hemolytic anemia; XR, extended release.

Oncology

			Clinical Proof of Concept	Pivotal	Approved
Zynyz® (retifanlimab-dlwr)⁹ Zynyz® (retifanlimab)⁹ PD-1	Squamous cell carcinoma of the anal canal ^{2,6,7} , Merkel cell carcinoma ^{2,5,6}				
Pemazyre® (pemigatinib) FGFR1/2/3	Cholangiocarcinoma ¹⁰				
retifanlimab⁹ PD-1	Non-small cell lung cancer				
	PROC with cyclin E1 overexpression				
INCB123667 CDK2	Solid tumors				
	Microsatellite-stable colorectal cancer				
INCA33890³ TGFβR2xPD-1	Solid tumors				
	KRAS G12D-mutated PDAC				
INCB161734 KRAS G12D	KRAS G12D-mutated PDAC				
	KRAS G12D-mutated solid tumors				
INCA036873³ CD70xCD3	Renal cell carcinoma				

Inflammation and Autoimmunity

Opzelura® (ruxolitinib) cream JAK1/JAK2	Atopic dermatitis ^{2,5} , vitiligo ^{2,5,6}			
ruxolitinib cream JAK1/JAK2	Pediatric vitiligo, hidradenitis suppurativa			
povorcitinib JAK1	Hidradenitis suppurativa, vitiligo, prurigo nodularis			
	Asthma			

Other

zilurgisertib ALK2	Fibrodysplasia ossificans progressiva			
---------------------------	---------------------------------------	--	--	--

Partnered Programs

Olumiant® (baricitinib)¹¹ JAK1/JAK2	Rheumatoid arthritis ¹² , COVID-19 ¹² , AD ^{6,7} , alopecia areata ¹²			
Tabrecta® (capmatinib)¹³ MET	NSCLC with METex14 ¹²			
axatilimab⁴ CSF-1R	Idiopathic pulmonary fibrosis ¹⁴			